Equillium, Inc.
Equillium, Inc. (EQ) Stock Competitors & Peer Comparison
See (EQ) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EQ | $0.56 | -20.66% | 20.7M | -1.49 | -$0.39 | N/A |
| VRTX | $409.95 | -11.29% | 121.3B | -122.99 | -$3.84 | N/A |
| REGN | $571.54 | +2.27% | 60.7B | 14.40 | $39.68 | +0.31% |
| ALNY | $417.24 | +3.84% | 55B | -171.25 | -$2.45 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $690.32 | +2.45% | 42.2B | 35.18 | $19.62 | N/A |
| BNTX | $111.37 | +3.75% | 26.5B | -30.19 | -$3.65 | N/A |
| SMMT | $29.32 | +8.31% | 21.8B | -86.24 | -$0.34 | N/A |
| RPRX | $37.76 | +1.75% | 21.3B | 15.46 | $2.45 | +2.28% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
Stock Comparison
EQ vs VRTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, VRTX has a market cap of 121.3B. Regarding current trading prices, EQ is priced at $0.56, while VRTX trades at $409.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas VRTX's P/E ratio is -122.99. In terms of profitability, EQ's ROE is -0.74%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, EQ is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check VRTX's competition here
EQ vs REGN Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, REGN has a market cap of 60.7B. Regarding current trading prices, EQ is priced at $0.56, while REGN trades at $571.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas REGN's P/E ratio is 14.40. In terms of profitability, EQ's ROE is -0.74%, compared to REGN's ROE of +0.14%. Regarding short-term risk, EQ is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check REGN's competition here
EQ vs ALNY Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ALNY has a market cap of 55B. Regarding current trading prices, EQ is priced at $0.56, while ALNY trades at $417.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ALNY's P/E ratio is -171.25. In terms of profitability, EQ's ROE is -0.74%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, EQ is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ALNY's competition here
EQ vs SGEN Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EQ is priced at $0.56, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EQ's ROE is -0.74%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EQ is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check SGEN's competition here
EQ vs ARGX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ARGX has a market cap of 42.2B. Regarding current trading prices, EQ is priced at $0.56, while ARGX trades at $690.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ARGX's P/E ratio is 35.18. In terms of profitability, EQ's ROE is -0.74%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, EQ is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ARGX's competition here
EQ vs BNTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, BNTX has a market cap of 26.5B. Regarding current trading prices, EQ is priced at $0.56, while BNTX trades at $111.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas BNTX's P/E ratio is -30.19. In terms of profitability, EQ's ROE is -0.74%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, EQ is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check BNTX's competition here
EQ vs SMMT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, SMMT has a market cap of 21.8B. Regarding current trading prices, EQ is priced at $0.56, while SMMT trades at $29.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas SMMT's P/E ratio is -86.24. In terms of profitability, EQ's ROE is -0.74%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, EQ is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check SMMT's competition here
EQ vs RPRX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, EQ is priced at $0.56, while RPRX trades at $37.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RPRX's P/E ratio is 15.46. In terms of profitability, EQ's ROE is -0.74%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, EQ is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RPRX's competition here
EQ vs BGNE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EQ is priced at $0.56, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EQ's ROE is -0.74%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, EQ is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check BGNE's competition here
EQ vs DNA-WT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EQ is priced at $0.56, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EQ's ROE is -0.74%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, EQ is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check DNA-WT's competition here
EQ vs INCY Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, INCY has a market cap of 15.2B. Regarding current trading prices, EQ is priced at $0.56, while INCY trades at $77.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas INCY's P/E ratio is 18.45. In terms of profitability, EQ's ROE is -0.74%, compared to INCY's ROE of +0.34%. Regarding short-term risk, EQ is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check INCY's competition here
EQ vs GMAB Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, GMAB has a market cap of 13.5B. Regarding current trading prices, EQ is priced at $0.56, while GMAB trades at $21.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas GMAB's P/E ratio is 12.93. In terms of profitability, EQ's ROE is -0.74%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, EQ is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check GMAB's competition here
EQ vs UTHR Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, UTHR has a market cap of 13.2B. Regarding current trading prices, EQ is priced at $0.56, while UTHR trades at $292.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas UTHR's P/E ratio is 11.41. In terms of profitability, EQ's ROE is -0.74%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EQ is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check UTHR's competition here
EQ vs KRTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EQ is priced at $0.56, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EQ's ROE is -0.74%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EQ is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check KRTX's competition here
EQ vs BMRN Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, EQ is priced at $0.56, while BMRN trades at $62.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas BMRN's P/E ratio is 22.34. In terms of profitability, EQ's ROE is -0.74%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, EQ is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check BMRN's competition here
EQ vs ASND Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ASND has a market cap of 11.1B. Regarding current trading prices, EQ is priced at $0.56, while ASND trades at $184.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ASND's P/E ratio is -27.69. In terms of profitability, EQ's ROE is -0.74%, compared to ASND's ROE of +1.91%. Regarding short-term risk, EQ is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ASND's competition here
EQ vs MRNA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MRNA has a market cap of 10.7B. Regarding current trading prices, EQ is priced at $0.56, while MRNA trades at $27.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MRNA's P/E ratio is -3.68. In terms of profitability, EQ's ROE is -0.74%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, EQ is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MRNA's competition here
EQ vs EXEL Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, EXEL has a market cap of 9.9B. Regarding current trading prices, EQ is priced at $0.56, while EXEL trades at $36.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas EXEL's P/E ratio is 17.70. In terms of profitability, EQ's ROE is -0.74%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, EQ is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check EXEL's competition here
EQ vs RXDX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EQ is priced at $0.56, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EQ's ROE is -0.74%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RXDX's competition here
EQ vs BBIO Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, BBIO has a market cap of 9.1B. Regarding current trading prices, EQ is priced at $0.56, while BBIO trades at $47.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas BBIO's P/E ratio is -13.41. In terms of profitability, EQ's ROE is -0.74%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, EQ is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check BBIO's competition here
EQ vs VRNA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, EQ is priced at $0.56, while VRNA trades at $105.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas VRNA's P/E ratio is -52.73. In terms of profitability, EQ's ROE is -0.74%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, EQ is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check VRNA's competition here
EQ vs IMGN Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EQ is priced at $0.56, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EQ's ROE is -0.74%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, EQ is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check IMGN's competition here
EQ vs TECH Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, EQ is priced at $0.56, while TECH trades at $54.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas TECH's P/E ratio is 66.12. In terms of profitability, EQ's ROE is -0.74%, compared to TECH's ROE of +0.06%. Regarding short-term risk, EQ is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check TECH's competition here
EQ vs BPMC Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, EQ is priced at $0.56, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas BPMC's P/E ratio is -51.58. In terms of profitability, EQ's ROE is -0.74%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, EQ is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check BPMC's competition here
EQ vs CERE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EQ is priced at $0.56, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CERE's P/E ratio is -16.47. In terms of profitability, EQ's ROE is -0.74%, compared to CERE's ROE of -0.43%. Regarding short-term risk, EQ is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CERE's competition here
EQ vs ROIVW Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, EQ is priced at $0.56, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, EQ's ROE is -0.74%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, EQ is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ROIVW's competition here
EQ vs ROIV Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, EQ is priced at $0.56, while ROIV trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ROIV's P/E ratio is -15.35. In terms of profitability, EQ's ROE is -0.74%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, EQ is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ROIV's competition here
EQ vs CORT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, EQ is priced at $0.56, while CORT trades at $71.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CORT's P/E ratio is 64.08. In terms of profitability, EQ's ROE is -0.74%, compared to CORT's ROE of +0.20%. Regarding short-term risk, EQ is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CORT's competition here
EQ vs HALO Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, EQ is priced at $0.56, while HALO trades at $60.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas HALO's P/E ratio is 15.95. In terms of profitability, EQ's ROE is -0.74%, compared to HALO's ROE of +1.22%. Regarding short-term risk, EQ is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check HALO's competition here
EQ vs JAZZ Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, EQ is priced at $0.56, while JAZZ trades at $116.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas JAZZ's P/E ratio is 15.77. In terms of profitability, EQ's ROE is -0.74%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, EQ is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check JAZZ's competition here
EQ vs MDGL Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MDGL has a market cap of 6.9B. Regarding current trading prices, EQ is priced at $0.56, while MDGL trades at $346.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MDGL's P/E ratio is -17.49. In terms of profitability, EQ's ROE is -0.74%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, EQ is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MDGL's competition here
EQ vs IONS Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, EQ is priced at $0.56, while IONS trades at $43.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas IONS's P/E ratio is -24.69. In terms of profitability, EQ's ROE is -0.74%, compared to IONS's ROE of -0.45%. Regarding short-term risk, EQ is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check IONS's competition here
EQ vs RVMD Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, EQ is priced at $0.56, while RVMD trades at $37.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RVMD's P/E ratio is -9.27. In terms of profitability, EQ's ROE is -0.74%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, EQ is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RVMD's competition here
EQ vs RETA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EQ is priced at $0.56, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RETA's P/E ratio is -66.29. In terms of profitability, EQ's ROE is -0.74%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EQ is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RETA's competition here
EQ vs RYTM Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RYTM has a market cap of 5.9B. Regarding current trading prices, EQ is priced at $0.56, while RYTM trades at $88.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RYTM's P/E ratio is -32.23. In terms of profitability, EQ's ROE is -0.74%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, EQ is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RYTM's competition here
EQ vs NUVL Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, EQ is priced at $0.56, while NUVL trades at $78.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas NUVL's P/E ratio is -17.74. In terms of profitability, EQ's ROE is -0.74%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check NUVL's competition here
EQ vs ABCM Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EQ is priced at $0.56, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EQ's ROE is -0.74%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EQ is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ABCM's competition here
EQ vs ISEE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EQ is priced at $0.56, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EQ's ROE is -0.74%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EQ is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ISEE's competition here
EQ vs ABVX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, EQ is priced at $0.56, while ABVX trades at $71.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ABVX's P/E ratio is -21.39. In terms of profitability, EQ's ROE is -0.74%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, EQ is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ABVX's competition here
EQ vs AXSM Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, AXSM has a market cap of 5.2B. Regarding current trading prices, EQ is priced at $0.56, while AXSM trades at $106.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas AXSM's P/E ratio is -18.46. In terms of profitability, EQ's ROE is -0.74%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, EQ is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check AXSM's competition here
EQ vs CRSP Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, EQ is priced at $0.56, while CRSP trades at $54.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CRSP's P/E ratio is -13.27. In terms of profitability, EQ's ROE is -0.74%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, EQ is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CRSP's competition here
EQ vs MRUS Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, EQ is priced at $0.56, while MRUS trades at $66.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MRUS's P/E ratio is -16.09. In terms of profitability, EQ's ROE is -0.74%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, EQ is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MRUS's competition here
EQ vs ADMA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ADMA has a market cap of 4.8B. Regarding current trading prices, EQ is priced at $0.56, while ADMA trades at $19.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ADMA's P/E ratio is 23.70. In terms of profitability, EQ's ROE is -0.74%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, EQ is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ADMA's competition here
EQ vs TGTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, EQ is priced at $0.56, while TGTX trades at $29.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas TGTX's P/E ratio is 114.88. In terms of profitability, EQ's ROE is -0.74%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, EQ is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check TGTX's competition here
EQ vs TLX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, TLX has a market cap of 4.5B. Regarding current trading prices, EQ is priced at $0.56, while TLX trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas TLX's P/E ratio is 148.00. In terms of profitability, EQ's ROE is -0.74%, compared to TLX's ROE of +0.06%. Regarding short-term risk, EQ is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check TLX's competition here
EQ vs RNA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RNA has a market cap of 4.5B. Regarding current trading prices, EQ is priced at $0.56, while RNA trades at $37.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RNA's P/E ratio is -12.44. In terms of profitability, EQ's ROE is -0.74%, compared to RNA's ROE of -0.27%. Regarding short-term risk, EQ is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RNA's competition here
EQ vs ALPN Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EQ is priced at $0.56, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EQ's ROE is -0.74%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, EQ is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ALPN's competition here
EQ vs SLNO Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, EQ is priced at $0.56, while SLNO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas SLNO's P/E ratio is -17.75. In terms of profitability, EQ's ROE is -0.74%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, EQ is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check SLNO's competition here
EQ vs ALKS Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, EQ is priced at $0.56, while ALKS trades at $26.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ALKS's P/E ratio is 12.87. In terms of profitability, EQ's ROE is -0.74%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, EQ is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ALKS's competition here
EQ vs CYTK Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, EQ is priced at $0.56, while CYTK trades at $36.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CYTK's P/E ratio is -6.91. In terms of profitability, EQ's ROE is -0.74%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, EQ is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CYTK's competition here
EQ vs PCVX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, EQ is priced at $0.56, while PCVX trades at $34.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas PCVX's P/E ratio is -8.45. In terms of profitability, EQ's ROE is -0.74%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, EQ is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check PCVX's competition here
EQ vs ZLAB Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ZLAB has a market cap of 4.2B. Regarding current trading prices, EQ is priced at $0.56, while ZLAB trades at $39.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ZLAB's P/E ratio is -15.22. In terms of profitability, EQ's ROE is -0.74%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, EQ is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ZLAB's competition here
EQ vs OPT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EQ is priced at $0.56, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas OPT's P/E ratio is -1.52. In terms of profitability, EQ's ROE is -0.74%, compared to OPT's ROE of +2.60%. Regarding short-term risk, EQ is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check OPT's competition here
EQ vs PTCT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, EQ is priced at $0.56, while PTCT trades at $51.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas PTCT's P/E ratio is 8.03. In terms of profitability, EQ's ROE is -0.74%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, EQ is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check PTCT's competition here
EQ vs MRTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EQ is priced at $0.56, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EQ's ROE is -0.74%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EQ is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MRTX's competition here
EQ vs ACAD Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, EQ is priced at $0.56, while ACAD trades at $24.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ACAD's P/E ratio is 17.55. In terms of profitability, EQ's ROE is -0.74%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, EQ is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ACAD's competition here
EQ vs ACLX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, EQ is priced at $0.56, while ACLX trades at $71.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ACLX's P/E ratio is -24.11. In terms of profitability, EQ's ROE is -0.74%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, EQ is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ACLX's competition here
EQ vs KRYS Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, KRYS has a market cap of 3.9B. Regarding current trading prices, EQ is priced at $0.56, while KRYS trades at $135.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas KRYS's P/E ratio is 32.28. In terms of profitability, EQ's ROE is -0.74%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, EQ is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check KRYS's competition here
EQ vs AKRO Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, EQ is priced at $0.56, while AKRO trades at $48.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas AKRO's P/E ratio is -12.97. In terms of profitability, EQ's ROE is -0.74%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, EQ is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check AKRO's competition here
EQ vs VKTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, EQ is priced at $0.56, while VKTX trades at $33.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas VKTX's P/E ratio is -22.06. In terms of profitability, EQ's ROE is -0.74%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, EQ is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check VKTX's competition here
EQ vs RYZB Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EQ is priced at $0.56, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EQ's ROE is -0.74%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EQ is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RYZB's competition here
EQ vs CBAY Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EQ is priced at $0.56, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EQ's ROE is -0.74%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EQ is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CBAY's competition here
EQ vs MTSR Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MTSR has a market cap of 3.6B. Regarding current trading prices, EQ is priced at $0.56, while MTSR trades at $34.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MTSR's P/E ratio is -11.71. In terms of profitability, EQ's ROE is -0.74%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, EQ is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MTSR's competition here
EQ vs SWTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, EQ is priced at $0.56, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas SWTX's P/E ratio is -13.78. In terms of profitability, EQ's ROE is -0.74%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, EQ is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check SWTX's competition here
EQ vs LEGN Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, EQ is priced at $0.56, while LEGN trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas LEGN's P/E ratio is -32.58. In terms of profitability, EQ's ROE is -0.74%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, EQ is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check LEGN's competition here
EQ vs SRRK Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, EQ is priced at $0.56, while SRRK trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas SRRK's P/E ratio is -14.51. In terms of profitability, EQ's ROE is -0.74%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, EQ is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check SRRK's competition here
EQ vs AAPG Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, AAPG has a market cap of 3.5B. Regarding current trading prices, EQ is priced at $0.56, while AAPG trades at $37.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas AAPG's P/E ratio is -50.13. In terms of profitability, EQ's ROE is -0.74%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, EQ is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check AAPG's competition here
EQ vs MLTX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, EQ is priced at $0.56, while MLTX trades at $53.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MLTX's P/E ratio is -23.18. In terms of profitability, EQ's ROE is -0.74%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MLTX's competition here
EQ vs PTGX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, EQ is priced at $0.56, while PTGX trades at $53.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas PTGX's P/E ratio is 69.01. In terms of profitability, EQ's ROE is -0.74%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, EQ is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check PTGX's competition here
EQ vs APLS Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, EQ is priced at $0.56, while APLS trades at $24.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas APLS's P/E ratio is -13.26. In terms of profitability, EQ's ROE is -0.74%, compared to APLS's ROE of -1.16%. Regarding short-term risk, EQ is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check APLS's competition here
EQ vs KYMR Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, EQ is priced at $0.56, while KYMR trades at $43.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas KYMR's P/E ratio is -14.04. In terms of profitability, EQ's ROE is -0.74%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, EQ is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check KYMR's competition here
EQ vs MORF Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, EQ is priced at $0.56, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MORF's P/E ratio is -14.88. In terms of profitability, EQ's ROE is -0.74%, compared to MORF's ROE of -0.22%. Regarding short-term risk, EQ is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MORF's competition here
EQ vs MOR Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, EQ is priced at $0.56, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MOR's P/E ratio is -12.64. In terms of profitability, EQ's ROE is -0.74%, compared to MOR's ROE of -1.84%. Regarding short-term risk, EQ is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MOR's competition here
EQ vs IMVT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, EQ is priced at $0.56, while IMVT trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas IMVT's P/E ratio is -5.89. In terms of profitability, EQ's ROE is -0.74%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, EQ is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check IMVT's competition here
EQ vs KDNY Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, EQ is priced at $0.56, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas KDNY's P/E ratio is -12.47. In terms of profitability, EQ's ROE is -0.74%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, EQ is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check KDNY's competition here
EQ vs RARE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, EQ is priced at $0.56, while RARE trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RARE's P/E ratio is -4.88. In terms of profitability, EQ's ROE is -0.74%, compared to RARE's ROE of -1.86%. Regarding short-term risk, EQ is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RARE's competition here
EQ vs CPRX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, EQ is priced at $0.56, while CPRX trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CPRX's P/E ratio is 13.84. In terms of profitability, EQ's ROE is -0.74%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, EQ is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CPRX's competition here
EQ vs CRNX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CRNX has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.56, while CRNX trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CRNX's P/E ratio is -7.43. In terms of profitability, EQ's ROE is -0.74%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, EQ is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CRNX's competition here
EQ vs MYOV Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.56, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MYOV's P/E ratio is -14.05. In terms of profitability, EQ's ROE is -0.74%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, EQ is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MYOV's competition here
EQ vs LGND Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.56, while LGND trades at $135.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas LGND's P/E ratio is -18.57. In terms of profitability, EQ's ROE is -0.74%, compared to LGND's ROE of -0.16%. Regarding short-term risk, EQ is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check LGND's competition here
EQ vs MIRM Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, EQ is priced at $0.56, while MIRM trades at $52.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas MIRM's P/E ratio is -32.43. In terms of profitability, EQ's ROE is -0.74%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, EQ is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check MIRM's competition here
EQ vs XENE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, XENE has a market cap of 2.5B. Regarding current trading prices, EQ is priced at $0.56, while XENE trades at $33.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas XENE's P/E ratio is -10.30. In terms of profitability, EQ's ROE is -0.74%, compared to XENE's ROE of -0.32%. Regarding short-term risk, EQ is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check XENE's competition here
EQ vs RXRX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, EQ is priced at $0.56, while RXRX trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas RXRX's P/E ratio is -3.22. In terms of profitability, EQ's ROE is -0.74%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, EQ is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check RXRX's competition here
EQ vs KNSA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, EQ is priced at $0.56, while KNSA trades at $33.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas KNSA's P/E ratio is 659.00. In terms of profitability, EQ's ROE is -0.74%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, EQ is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check KNSA's competition here
EQ vs NAMS Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, EQ is priced at $0.56, while NAMS trades at $21.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas NAMS's P/E ratio is -11.77. In terms of profitability, EQ's ROE is -0.74%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, EQ is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check NAMS's competition here
EQ vs PRVB Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, EQ is priced at $0.56, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas PRVB's P/E ratio is -16.43. In terms of profitability, EQ's ROE is -0.74%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, EQ is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check PRVB's competition here
EQ vs NAMSW Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.56, while NAMSW trades at $10.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas NAMSW's P/E ratio is N/A. In terms of profitability, EQ's ROE is -0.74%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, EQ is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check NAMSW's competition here
EQ vs LBPH Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.56, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas LBPH's P/E ratio is -26.66. In terms of profitability, EQ's ROE is -0.74%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, EQ is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check LBPH's competition here
EQ vs ARWR Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.56, while ARWR trades at $16.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas ARWR's P/E ratio is -13.28. In terms of profitability, EQ's ROE is -0.74%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, EQ is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check ARWR's competition here
EQ vs BLTE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, BLTE has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.56, while BLTE trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas BLTE's P/E ratio is -51.32. In terms of profitability, EQ's ROE is -0.74%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, EQ is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check BLTE's competition here
EQ vs DICE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, EQ is priced at $0.56, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas DICE's P/E ratio is -21.91. In terms of profitability, EQ's ROE is -0.74%, compared to DICE's ROE of +0.56%. Regarding short-term risk, EQ is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check DICE's competition here
EQ vs APGE Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.56, while APGE trades at $37.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas APGE's P/E ratio is -10.31. In terms of profitability, EQ's ROE is -0.74%, compared to APGE's ROE of -0.19%. Regarding short-term risk, EQ is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check APGE's competition here
EQ vs GLPG Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.56, while GLPG trades at $33.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas GLPG's P/E ratio is -6.66. In terms of profitability, EQ's ROE is -0.74%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, EQ is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check GLPG's competition here
EQ vs IDYA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.56, while IDYA trades at $25.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas IDYA's P/E ratio is -6.85. In terms of profitability, EQ's ROE is -0.74%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, EQ is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check IDYA's competition here
EQ vs IBRX Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, EQ is priced at $0.56, while IBRX trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas IBRX's P/E ratio is -4.21. In terms of profitability, EQ's ROE is -0.74%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, EQ is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check IBRX's competition here
EQ vs CNTA Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CNTA has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.56, while CNTA trades at $15.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CNTA's P/E ratio is -8.55. In terms of profitability, EQ's ROE is -0.74%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, EQ is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CNTA's competition here
EQ vs CALT Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.56, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas CALT's P/E ratio is -22.73. In terms of profitability, EQ's ROE is -0.74%, compared to CALT's ROE of -1.67%. Regarding short-term risk, EQ is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check CALT's competition here
EQ vs FOLD Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, FOLD has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.56, while FOLD trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas FOLD's P/E ratio is -56.92. In terms of profitability, EQ's ROE is -0.74%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, EQ is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check FOLD's competition here
EQ vs AGIO Comparison August 2025
EQ plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EQ stands at 20.7M. In comparison, AGIO has a market cap of 2.1B. Regarding current trading prices, EQ is priced at $0.56, while AGIO trades at $35.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EQ currently has a P/E ratio of -1.49, whereas AGIO's P/E ratio is 3.13. In terms of profitability, EQ's ROE is -0.74%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, EQ is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for EQ.Check AGIO's competition here